17 September 2025
Novo Nordisk's Oral Semaglutide Achieves 16.6% Weight Loss in Obesity Study
Oral semaglutide 25 mg shows significant weight loss and improved physical activity in a 64-week trial, with mild to moderate side effects, pending FDA approval.
